Bispecific antibodies: advancing precision oncology
Uložené v:
| Názov: | Bispecific antibodies: advancing precision oncology |
|---|---|
| Autori: | Mercedes Herrera, Giulia Pretelli, Jayesh Desai, Elena Garralda, Lillian L. Siu, Thiago M. Steiner, Lewis Au |
| Prispievatelia: | Institut Català de la Salut, [Herrera M, Siu LL] Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada. [Pretelli G] Department of Medical Oncology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Desai J] Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia. Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia. [Garralda E] Department of Medical Oncology, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Steiner TM] Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia. Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia, Vall d'Hebron Barcelona Hospital Campus |
| Zdroj: | Scientia Scientia. Dipòsit d'Informació Digital del Departament de Salut instname |
| Informácie o vydavateľovi: | Elsevier BV, 2024. |
| Rok vydania: | 2024 |
| Predmety: | Other subheadings::Other subheadings::/therapeutic use, Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia, FENÓMENOS Y PROCESOS::fenómenos fisiológicos::fenómenos farmacológicos y toxicológicos::fenómenos farmacológicos::resistencia a medicamentos::resistencia a los antineoplásicos, Otros calificadores::Otros calificadores::/uso terapéutico, Medicaments antineoplàstics - Ús terapèutic, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::medicina de precisión, DISEASES::Neoplasms, Antineoplastic Agents, Immunological, COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antineoplásicos::inmunoterapia antineoplásica, Neoplasms, CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents::Antineoplastic Agents, Immunological, Antibodies, Bispecific, PHENOMENA AND PROCESSES::Physiological Phenomena::Pharmacological and Toxicological Phenomena::Pharmacological Phenomena::Drug Resistance::Drug Resistance, Neoplasm, Humans, Animals, Medicina personalitzada, Molecular Targeted Therapy, Precision Medicine, Resistència als medicaments, COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas sanguíneas::inmunoproteínas::inmunoglobulinas::anticuerpos::anticuerpos biespecíficos, Other subheadings::Other subheadings::Other subheadings::/drug therapy, Anticossos monoclonals - Ús terapèutic, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Precision Medicine, CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Immunoproteins::Immunoglobulins::Antibodies::Antibodies, Bispecific, ENFERMEDADES::neoplasias, Drug Resistance, Neoplasm, Càncer - Immunoteràpia |
| Popis: | Bispecific antibodies (bsAbs) are engineered molecules designed to target two different epitopes or antigens. The mechanism of action is determined by the bsAb molecular targets and structure (or format), which can be manipulated to create variable and novel functionalities, including linking immune cells with tumor cells, or dual signaling pathway blockade. Several bsAbs have already changed the treatment landscape of hematological malignancies and select solid cancers. However, the mechanisms of resistance to these agents are understudied and the management of toxicities remains challenging. Herein, we review the principles in bsAb engineering, current understanding of mechanisms of action and resistance, data for clinical application, and provide a perspective on ongoing challenges and future developments in this field. |
| Druh dokumentu: | Article |
| Popis súboru: | application/pdf |
| Jazyk: | English |
| ISSN: | 2405-8033 |
| DOI: | 10.1016/j.trecan.2024.07.002 |
| Prístupová URL adresa: | https://pubmed.ncbi.nlm.nih.gov/39214782 https://hdl.handle.net/11351/12573 |
| Rights: | CC BY NC ND |
| Prístupové číslo: | edsair.doi.dedup.....cfbb676b37410c4763e0a666627a8ea1 |
| Databáza: | OpenAIRE |
Nájsť tento článok vo Web of Science | Abstrakt: | Bispecific antibodies (bsAbs) are engineered molecules designed to target two different epitopes or antigens. The mechanism of action is determined by the bsAb molecular targets and structure (or format), which can be manipulated to create variable and novel functionalities, including linking immune cells with tumor cells, or dual signaling pathway blockade. Several bsAbs have already changed the treatment landscape of hematological malignancies and select solid cancers. However, the mechanisms of resistance to these agents are understudied and the management of toxicities remains challenging. Herein, we review the principles in bsAb engineering, current understanding of mechanisms of action and resistance, data for clinical application, and provide a perspective on ongoing challenges and future developments in this field. |
|---|---|
| ISSN: | 24058033 |
| DOI: | 10.1016/j.trecan.2024.07.002 |